Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adults 56 years of age and older: a Phase II randomized study

Judith Kirstein, Miriam Pina, Judy Pan, Emilia Jordanov, Mandeep S Dhingra, Judith Kirstein, Miriam Pina, Judy Pan, Emilia Jordanov, Mandeep S Dhingra

Abstract

MenACYW-TT is an investigational quadrivalent meningococcal conjugate vaccine intended for the prevention of invasive meningococcal disease (IMD) caused by serogroups A, C, W, and Y in individuals aged 6 weeks and above. This Phase II, randomized, open-label, multicenter, exploratory study assessed the safety and immunogenicity of MenACYW-TT compared with a quadrivalent meningococcal polysaccharide vaccine (MPSV4) in 301 healthy adults aged ≥56 y in the US (NCT01732627). Participants were randomized 2:1 to receive MenACYW-TT or MPSV4. Serum bactericidal assays using human (hSBA) or baby rabbit (rSBA) complement were used to measure functional antibodies against meningococcal serogroups A, C, W, and Y at baseline and 30 d post-vaccination. Safety data were collected up to 30 d post-vaccination. Proportions of study participants with hSBA titers ≥1:8 against serogroups A, C, W, and Y were increased at Day 30 compared with baseline in both vaccine groups. The proportions of participants with hSBA titers ≥1:8 after MenACYW-TT vaccination were comparable to those after MPSV4 vaccination for serogroups A and C (A: 93.8% vs. 85.1%; C: 74.9% vs. 62.8%) and distinctly higher than after MPSV4 for serogroups W and Y (W: 79.5% vs. 60.6%; Y: 80.5% vs. 59.6%). Proportions of participants with rSBA titers ≥1:8 were comparable between vaccine groups for all four serogroups. The reactogenicity profiles of both vaccines were similar. Most unsolicited adverse events (AEs) were of Grade 1 or Grade 2 intensity, and no serious AEs were reported. The MenACYW-TT conjugate vaccine was well tolerated and immunogenic in adults aged ≥56 y.

Keywords: MPSV4; MenACYW-TT; invasive meningococcal disease; older adults; vaccine.

Figures

Figure 1.
Figure 1.
Proportion of participants with an hSBA vaccine seroresponse* at Day 30 (PPAS) *Vaccine seroresponse is defined as a post-vaccination titer ≥1:8 if baseline titer is

Figure 2.

Proportion of participants with rSBA…

Figure 2.

Proportion of participants with rSBA titers ≥1:128 at (a) baseline and (b) Day…

Figure 2.
Proportion of participants with rSBA titers ≥1:128 at (a) baseline and (b) Day 30 (PPAS).
Figure 2.
Figure 2.
Proportion of participants with rSBA titers ≥1:128 at (a) baseline and (b) Day 30 (PPAS).

References

    1. Borrow R, Alarcon P, Carlos J, Caugant DA, Christensen H, Debbag R, De Wals P, Echániz-Aviles G, Findlow J, Head C, et al. The global meningococcal initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev Vaccines. 2017;16:313–28. doi:10.1080/14760584.2017.1258308.
    1. Wang B, Santoreneos R, Giles L, Haji Ali Afzali H, Marshall H.. Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis. Vaccine. 2019;37:2768–82. doi:10.1016/j.vaccine.2019.04.020.
    1. Zahlanie YC, Hammadi MM, Ghanem ST, Dbaibo GS. Review of meningococcal vaccines with updates on immunization in adults. Hum Vaccin Immunother. 2014;10:995–1007. doi:10.4161/hv.27739.
    1. Harrison LH. Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis. 2010;1:648963.
    1. Whittaker R, Dias JG, Ramliden M, Kodmon C, Economopoulou A, Beer N, Pastore Celentano L, Kanitz E, Richter L, Mattheus W, et al. The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004–2014. Vaccine. 2017;35:2034–41. doi:10.1016/j.vaccine.2017.03.007.
    1. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007;369:2196–210. doi:10.1016/S0140-6736(07)61016-2.
    1. Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol. 2012;799:1–20.
    1. Baccarini C, Ternouth A, Wieffer H, Vyse A. The changing epidemiology of meningococcal disease in North America 1945–2010. Hum Vaccin Immunother. 2013;9:162–71. doi:10.4161/hv.22302.
    1. Pelton SI. The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines. J Adolesc Health. 2016;59:S3–S11. doi:10.1016/j.jadohealth.2016.04.012.
    1. Soeters HBA, Chang H-Y, Whaley M, Macneil J.. Current epidemiology of serogroup W meningococcal disease—United States, 2010–2015. Open Forum Infect Dis. 2017;4(Suppl. 7):S7–S7. doi:10.1093/ofid/ofx162.017.
    1. Mbaeyi SA, Blain A, Whaley MJ, Wang X, Cohn AC, MacNeil JR. Epidemiology of meningococcal disease outbreaks in the United States, 2009–2013. Clin Infect Dis. 2018;30:580–85.
    1. MacNeil JR, Blain AE, Wang X, Cohn AC. Current epidemiology and trends in meningococcal disease—United States, 1996–2015. Clin Infect Dis. 2018;66:1276–81. doi:10.1093/cid/cix993.
    1. Centers for Disease Control and Prevention . Age as a risk factor. 2017. [accessed 2018 December19]. .
    1. Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec. 2011;86:521–39.
    1. Pina LM, Bassily E, Machmer A, Hou V, Reinhardt A. Safety and immunogenicity of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants and toddlers: three multicenter phase III studies. Pediatr Infect Dis J. 2012;31:1173–83. doi:10.1097/INF.0b013e318268dfe4.
    1. Maslanka SE, Gheesling LL, Libutti DE, Donaldson KB, Harakeh HS, Dykes JK, Arhin FF, Devi SJ, Frasch CE, Huang JC, et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The multilaboratory study group. Clin Diagn Lab Immunol. 1997;4:156–67. doi:10.1128/CDLI.4.2.156-167.1997.
    1. Santos GF, Deck RR, Donnelly J, Blackwelder W, Granoff DM. Importance of complement source in measuring meningococcal bactericidal titers. Clin Diagn Lab Immunol. 2001;8:616–23. doi:10.1128/CDLI.8.3.616-623.2001.
    1. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129:1307–26. doi:10.1084/jem.129.6.1307.
    1. Findlow H, Plikaytis BD, Aase A, Bash MC, Chadha H, Elie C, Laher G, Martinez J, Herstad T, Newton E, et al. Investigation of different group A immunoassays following one dose of meningococcal group A conjugate vaccine or A/C polysaccharide vaccine in adults. Clin Vaccine Immunol. 2009;16:969–77. doi:10.1128/CVI.00068-09.
    1. Gill CJ, Ram S, Welsch JA, Detora L, Anemona A. Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source. Vaccine. 2011;30:29–34. doi:10.1016/j.vaccine.2011.10.068.
    1. McIntosh ED, Broker M, Wassil J, Welsch JA, Borrow R. Serum bactericidal antibody assays - The role of complement in infection and immunity. Vaccine. 2015;33:4414–21. doi:10.1016/j.vaccine.2015.07.019.
    1. Gunaratnam P, Massey P, Durrheim D, Torvaldsen S. Invasive meningococcal disease in elderly people, New South Wales, Australia, 1993 to 2012. West Pac Surveillance Response J: WPSAR. 2013;4:4–10. doi:10.5365/WPSAR.2013.4.4.001.
    1. Weinberger B. Vaccines for the elderly: current use and future challenges. Immun Ageing. 2018;15:017–0107. doi:10.1186/s12979-017-0107-2.
    1. The Embassy of the Kingdom of Saudi Arabia . Hajj and Umrah Health Requirements; 2018. December 19 [accessed 2020 Mar 5]. .
    1. Centers for Disease Control and Prevention . Menomune (Meningococcal polysaccharide vaccine) discontinuation. 2017. [accessed 2018 December19]. .
    1. Timo Vesikari RB, Forsten A, Findlow H, Dhingra MS, Jordanov E. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study. Hum Vaccin Immunother. 2020. Submitted.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться